Several lawsuits filed against the manufacturers of the GLP-1 drugs Ozempic, Wegovy, and Mounjaro claim that some patients experienced sudden vision loss after taking the medications. The complaints were filed against Eli Lilly and Novo Nordisk.
Multiple lawsuits were filed against the manufacturers of the GLP-1 drugs Ozempic, Wegovy, and Mounjaro, according to the Wall Street Journal. The complaints claim that patients were not warned of a specific potential side effect caused by the drugs known as non-arteritic anterior ischemic optic neuropathy, or NAION.
The vision loss is usually permanent, but folks with diabetes are reportedly at an increased risk regardless of using GLP-1 drugs, according to ABC News.
However, the manufacturer of Wegovy and Ozempic, Novo Nordisk, said that the lawsuits are “without merit,” according to ABC News. A statement from Novo reportedly says that the company takes “all reports of adverse events very seriously,” and “Novo believes the personal injury lawsuits filed in the U.S. are without merit and are vigorously defending them.”
The manufacturer Mounjaro and Zepbound, Eli Lilly, also shared a statement about safety.
“Patient safety is Lilly’s top priority,” it reads, per ABC News. “We actively monitor, evaluate, and report safety information for all our medicines to the FDA. As part of our routine safety review process, we have ongoing discussions with regulators regarding potential safety topics, and we will continue to review data, including any data regarding ophthalmic issues.”
The FDA also issued a statement saying they monitored the drugs for safety, per ABC News.
“The FDA routinely monitors the safety of drug products postmarketing,” it reads. “The FDA identifies safety signals from a variety of sources, evaluates the available data, and takes regulatory actions when appropriate.”
WHDH in Boston reports that thousands of personal-injury vision-loss lawsuits have been filed against the drug makers. Researchers have reportedly been studying a link between GLP-12 drugs and NAION since 2024. However, no study has proved that GLP-1 drugs cause the disorder.
Roomies reacted to the news after it was shared on TSR‘s Instagram page. Several folks noted that they’d used a GLP-1 drug and had no issues, while others issued jokes.
User @breeeeia wrote, “I’ll just keep my back big because baby I’m already squinting as it is 😭.”
User @xo_.honey wrote, “They tell you on that LONGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG paper that comes in the box lol.”
User @livin.laviissh replied, “Yeah im not sacrificing my eyesight to lose a couple pounds like how am i supposed to see the changes? 😂😂😂😂.”
@datboul_jaereal added, “Walking around blind and skinny like stinkmeaner from the boondocks😂😂😂.”
@domdomda_bomb issued a warning. “My bf mom is a diabetic on Mounjaro and lost almost all of her eyesight in her right eye. Be careful everyone and stay prayed up.”
User @shawndean773 joked, “They said you wanna be big… or you wanna see!?.”
@_coachg30 noted, “Hopefully they see it through.”
@tammiethehairtrapper wrote, “Everybody gone be fine & blind .. 😂😂😂.”
User @katrinarosee26 added, “The only thing i can’t see is my waist. Bye!.”
@therealashleywalker replied, “These comments are diabolical 😂.”
User @matthew_bowman05 wrote, “You might be blind, but you gone be fine!”
According to ConsumerNotice.org, several lawsuits also claim the drug Ozempic causes a stomach paralysis known as gastroparesis, per the National Institute of Diabetes and Digestive and Kidney Diseases.
The condition slows or stops food from moving from the stomach to the small intestine despite there being no stomach or intestinal blockage.
The lawsuits claim that Ozempic and other GLP-1 drugs were linked to gastroparesis, as well as intestinal blockages called ileus. Symptoms included severe nausea, vomiting lasting for weeks, abdominal pain, significant weight loss, and vision loss (NAION).
The post Multiple Lawsuits Against GLP-1 Manufacturers Claim Drugs Carry Risk Of Sudden Vision Loss appeared first on The Shade Room.
Loading ...